Evidence map›Paper›PMID 33455090›Full record

SynthesisArthritis & rheumatology (Hoboken, N.J.)2021

Contribution of a European-Prevalent Variant near CD83 and an East Asian-Prevalent Variant near IL17RB to Herpes Zoster Risk in Tofacitinib Treatment: Results of Genome-Wide Association Study Meta-Analyses.

Nan Bing, Huanyu Zhou, Xing Chen, Tomohiro Hirose, Yuta Kochi, Yumi Tsuchida, Kazuyoshi Ishigaki, Shuji Sumitomo, Keishi Fujio, Baohong Zhang and 4 more

Open access · hybridAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Arthritis & rheumatology (Hoboken, N.J.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Article
  8. Pharmaco-Omics in Psoriasis: Paving the Way towards Personalized Medicine.International journal of molecular sciences · 2023
    Review
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Nan BingPfizer, Cambridge, Massachusetts.
Huanyu ZhouPfizer, Cambridge, Massachusetts.
Xing ChenPfizer, Cambridge, Massachusetts.
Tomohiro HirosePfizer Japan, Tokyo, Japan.
Yuta KochiCenter for Integrative Medical Sciences, RIKEN, Yokohama, Japan, and Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan.
Yumi TsuchidaUniversity of Tokyo Graduate School of Medicine, Tokyo, Japan.
Kazuyoshi IshigakiCenter for Integrative Medical Sciences, RIKEN, Yokohama, Japan.
Shuji SumitomoUniversity of Tokyo Graduate School of Medicine, Tokyo, Japan.
Keishi FujioUniversity of Tokyo Graduate School of Medicine, Tokyo, Japan.
Baohong ZhangPfizer, Cambridge, Massachusetts.
Hernan ValdezPfizer, New York, New York.
Michael S VincentPfizer, Cambridge, Massachusetts.
David MartinPfizer, Cambridge, Massachusetts.
James D ClarkPfizer, Cambridge, Massachusetts.
Pfizer (United States) · USThe University of Tokyo · JPRIKEN Center for Integrative Medical Sciences · JPPfizer (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA), psoriatic arthritis, and ulcerative colitis, and has been previously investigated for psoriasis (PsO). This meta-analysis of genome-wide association studies (GWAS) was performed to identify genetic factors associated with increased risk/faster onset of herpes zoster (HZ) in subjects with RA or PsO receiving tofacitinib treatment, and to determine potential mechanisms that could be attributed to the varying rates of HZ across ethnicities.

methodsIn an ethnicity/indication-specific, trans-ethnic, trans-population meta-analysis of GWAS in subjects with RA or PsO from phase II, phase III, and long-term extension studies of tofacitinib, 8 million genetic variants were evaluated for their potential association with time to an HZ event and incidence of an HZ event (case versus control) with tofacitinib treatment, using Cox proportional hazard and logistic regression analyses, respectively.

resultsIn total, 5,246 subjects were included (3,168 with RA and 2,078 with PsO). After adjustment for age, baseline absolute lymphocyte count, genetically defined ethnicity, and concomitant methotrexate use (in RA subjects only), 4 loci were significantly associated with faster onset of HZ in European subjects (P < 5 × 10

conclusionGenetic analysis of tofacitinib-treated subjects with RA or PsO identified multiple loci associated with increased HZ risk. Prevalent variants near the immune-relevant genes CD83 and IL17RB in European and East Asian populations, respectively, may contribute to risk of HZ in tofacitinib-treated subjects.

Indexed as

Antigens, CDArthritis, RheumatoidAsian PeopleCD83 AntigenGenome-Wide Association StudyHerpes ZosterHumansImmunoglobulinsJanus Kinase InhibitorsLogistic ModelsMembrane GlycoproteinsPiperidinesPolymorphism, Single NucleotideProportional Hazards ModelsPsoriasisPyrimidinesAntigens, CDCD83 AntigenIL17RB protein, humanImmunoglobulinsJanus Kinase InhibitorsMembrane GlycoproteinsPiperidinesPyrimidinesReceptors, Interleukin-17tofacitinib

Identifiers

PMID33455090
PMCPMC8361995
OpenAlexW3124820301

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.